EACS 15-18. Oktober in Paris
EACS 2025 Publikationen - ViiV
|
CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment |
|
|
The Power of Choice: Perspectives From Healthcare Providers on Early Switch to CAB+RPV LA After
Rapid Suppression With DTG/3TC |
|
|
Real-World Effectiveness and Tolerability of Cabotegravir + Rilpivirine Long-Acting in People
Living with HIV-1: A Meta-Analysis of Real-World Evidence |
|
|
Real-World Utilization of Cabotegravir/Rilpivirine Long-Acting Injectable: An Observational
Analysis of Adherence and Persistence using a Patient Support Program in Canada |
|
|
High Effectiveness and Rare Virologic Failure in Treatment-Experienced Individuals on Long-Acting
Cabotegravir + Rilpivirine Therapy Across Europe: Insights from the EuroSIDA Study |
|
|
DOLUTEGRAVIR-based regimens |
|
|
PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine in
Europe (PAIRED Europe): Primary Analysis |
|
|
The European REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability
of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV |
|
|
Real-world Effectiveness of DTG+3TC in PLHIV With Previous ART Experience but no Genotype
Testing: The “AReTi” Study Results |
|
|
CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen
Dolutegravir/Lamivudine fixed dose combination in treatment-naïve adults and pre-treated adults who are virologically
suppressed, in routine clinical care, in France |
|
|
TR-DOLA: Real-world data on the use of Dolutegravir (DTG) + Lamivudine (3TC) in
treatment-experienced people living with HIV in TURKIYE |
|
*denotes ViiV-supported investigator led and collaborative studies
Kollegen Fragen
Diese Seite weiter empfehlen
